Musashi-2 (MSI2) promotes neuroblastoma tumorigenesis through targeting MYC-mediated glucose-6-phosphate dehydrogenase (G6PD) transcriptional activation-Reference-Cited by-同舟云学术

Musashi-2 (MSI2) promotes neuroblastoma tumorigenesis through targeting MYC-mediated glucose-6-phosphate dehydrogenase (G6PD) transcriptional activation

Published:2023-10-16 Issue:11 Volume:40 Page:
ISSN:1559-131X
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Jiang Ping,Zhang Ting,Wu Bin,Li Xiaoqing,Fu Mingpeng,Xu Banglao^ORCID

Funder

Guangzhou Municipal Science and Technology Project

National Nature Science Foundation of China

Basic and Applied Basic Research Foundation of Guangdong Province

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12032-023-02199-z.pdf

Reference42 articles.

1. Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33(27):3008–17.

2. Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawa A, Goto S, et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children’s Cancer Group. Cancer. 2001;92(9):2451–61.

3. DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999;21(3):181–9.

4. Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202–11.

5. Mora J, Cheung NKV, Gerald WL. Genetic heterogeneity and clonal evolution in neuroblastoma. Br J Cancer. 2001;85(2):182–9.